This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.
Similar Posts
Guidance Documents for Rare Disease Drug Development
Guidance Documents for Rare Disease Drug DevelopmentNatural Disaster Preparedness and Response | Drugs
Stay informed on FDA’s guidance for drugs used in natural disaster preparedness and response. Learn about emergency drug supplies, FDA-approved treatments, and safety measures for public health during disasters like hurricanes, floods, and more.VITAFER-L Gold 500ml may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use VITAFER-L Gold 500ml, a product promoted for energy and sexual enhancement on various websites, including www.amazon.com and www.walmart.com.Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.Maria A. Carballosa, M.D. – 720805 – 12/12/2025
In Vivo Bioavailability-Bioequivalence Studies – ClinicalIndulgeRx Brands, Inc – 703668 – 06/16/2025
New Drug/Misbranded